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344 Abstractslanding zone, of whom 3 with concomitant extra-anatomic
debranching of the supra-aortic vessels. Technical success was
achieved in 100%. The 30-day mortality rate was 16.7% (n ¼ 4).
Two patients had paraplegia. Neither stroke nor renal insufﬁciency
requiring new dialysis occurred. During a mean follow-up of 28
months, another death in relation with dissection occurred and 8
patients (33%) required reintervention. All reintervention were
managed by endovascular means. At last follow up CT-scan, 8
patients (33%) had complete remodeling of the aortic wall.
Conclusion: This study conﬁrms the feasibility of TEVAR for R-BAD
and its lower perioperative morbidity and mortality rate compared
to open surgery, reducing by more than 2 third the 30-day mor-
tality. However the rate of reintervention is high and a long term
follow up is mandatory.
Dipeptidyl Peptidase-4 Inhibitor Alogliptin Prevents Further
Dilatation of Abdominal Aortic Aneurysm Through Anti-oxidant
and Anti-inﬂammatory Effect in Rats
J. Yu
Kobe University Graduate School of Medicine, Japan
Introduction: Dipeptidyl peptidase-4 inhibitor alogliptin has been
proved to prevent abdominal aortic aneurysm (AAA) formation.
However, the mechanism of alogliptin on aneurysm development
has not been sufﬁciently investigated. The objective of this study
was to determine how alogliptin prevents further dilation of AAA
development mimicking clinical setting.
Methods: The AAA model induced with intraluminal elastase and
extraluminal calcium chloride was created in 42 rats. Forty-two rats
were divided 3 groups: a low-dose of alogliptin group (Group LD; 1
mg/kg/day), a high-dose group (Group HD; 3 mg/kg/day), and a
control group (Group C, water). Alogliptin administration by gastric
gavage once per daywas started on 7 days after aneurysm formation
(Dilatation ratio: 158.9 7.7%). On day 14, reactive oxygen species
(ROS) expression and the oxidation product of DNA 8-
hydroxydeoxyguanosine (8-OHdG) was measured. As ROS have
been reported to activate ERK pathway which is important modu-
lator of MMPs and inﬂammatory cytokines, MMP expression and
inﬂammatory response were also analyzed along with ERK evalua-
tion. Histopathological examination was performed on day 28, and
the AAA dilatation ratio was calculated to evaluate alogliptin pro-
tective effect.
Results: On day 14, ROS expression and 8-OHdG positive cells in
aneurysm walls were decreased by alogliptin treatment (ROS
expression: 4.4  0.6 in Group C, 3.2  0.1 in Group LD, and 2.7 
0.3 in Group HD, p < 0.001; 8-OHdG-positive cells: 167.4  6.9
cells in Group C, 102.7  19.9 cells in Group LD, and 64.7  2.7
cells in Group HD, p < 0.001). Western blot analysis showed
decrease ERK levels in treatment groups compared with in control
group. The treatment signiﬁcantly reduced mRNA expression of
MMPs, TNF-a and MCP-1 in aneurysm walls. Immunohistochemical
staining for CD68 demonstrated the decrease of macrophage
inﬁltration in aneurysm wall with treatment groups. On day 28, the
aortic wall in groups LD and HD were less dilated, and had higher
elastin content than those in Group C (Dilatation ratio: 199.2 
10.8% in Group C, 170.0  4.4% in Group LD, and 155.1  2.3% in
Group HD, p < 0.001).
Conclusion: Alogliptin treatment starting after aneurysm forma-
tion inhibits further dilation in rat model through anti-oxidant and
anti-inﬂammatory effect. Inhibition of ERK activation by reducing
oxidative stress prevented inﬂammatory response and matrix
degeneration, resulting in prevention of the aortic dilatation.High Frequency of AAA in the North of Sweden Not Explained by
Higher AAA Prevalence Among Siblings or Smoking
J. Forsberg *, A. Linné *, K. Leander, D. Lindström, R. Hultgren
Dept of Clinical Science and Education, Karolinska Institutet at Södersjukhuset,
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Introduction: The frequency of Abdominal Aortic Aneurysm (AAA)
is higher in the north region of Sweden compared to the south
with a 38% higher incidence for AAA in men. Smoking is less
common in the north and can subsequently not be responsible for
the increased risk. A strong hereditary trait has been suggested as
an explanation to the regional differences in disease pattern.
Organized screening for AAA in siblings is currently not arranged in
either region. Our aim was to investigate if siblings to AAA-patients
in the north part of Sweden have a higher prevalence of AAA
compared to siblings in the Stockholm region (mid).
Methods: All patients treated for AAA between Jan 2008eAug
2012 at two hospitals covering a large county of the north were
screened for siblings (n ¼ 483). The living siblings residing in the
north were offered an ultrasound scan of the abdominal aorta
preceded by a structured telephone interview regarding health
and medications. Ultrasound was performed by one validated
examiner using both LELE and OTO-technique. The result of the
ultrasound-examination was compared to the previously published
results of the prevalence of AAA in siblings in Stockholm (mid
Sweden).
Results: 379 siblings were included of which 8 had undergone
aortic repair and 8 had a known AAA under surveillance. 363 were
screened with ultrasound. The prevalence of AAA in all siblings was
34/379 (10%, brothers 14%, sisters 6%). There was no difference in
the prevalence of AAA in siblings from north compared to mid
region (p ¼ 0.75). Smoking was as common in both regions among
siblings with AAA.
Conclusion: Our data do not support a strong hereditary trait for
AAA in the north part of Sweden compared to other regions. The
results reinforce the importance of developing structured
screening protocols for ﬁrst degree relatives to AAA patients, since
the prevalence in siblings is strikingly high as compared to the
prevalence of AAA in the general population.Autologous Alternative Veins Do Not Provide Better Mid-term
Outcomes than Prosthetic Conduits for Below Knee Bypass When
Great Saphenous Vein is Unavailable
E.D. Avgerinos, A. Naddaf, U. Sachdev, D. Doucet, A. Mohapatra,
S.A. Leers, R.A. Chaer, M.S. Makaroun
University of Pittsburgh Medical Center, Pittsburg, USA
Introduction: Ipsilateral, single segment great saphenous vein
(GSV) remains the optimal conduit for below knee bypass to treat
critical limb ischemia. There is a need to better deﬁne the beneﬁt
of alternative autologous vein (AAV) segments over contemporary
prosthetic conduits in patients in whom GSV is not available.
Methods: Patients who underwent bypass to below-knee targets
for chronic arterial occlusive disease between 2007e2011 were
retrospectively reviewed and categorized in three groups: GSV;
AAV (small saphenous veins, arm veins or spliced vein segments);
Prosthetic. The primary outcome was graft patency (primary,
assisted primary, secondary). Secondary outcome was limb
salvage. Cox regression models were used to assess the effect of
baseline predictors. Results were considered statistically signiﬁcant
when p-value was <0.05.
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(popliteal 122 (29%), tibial 238 (56%), pedal 63 (15%)) were
analyzed.
258 (61%) patients received a single segment GSV, 118 (28%) an
AAV and 47 (11%) a prosthetic conduit. Postoperative outcomes
had no signiﬁcant differences among groups. Primary patency at 2
years for the GSV, AAV and prosthetic groups was 47%, 26% and
40% respectively. AAV demonstrated the poorest primary patency
rates, though non-statistically signiﬁcant compared to the pros-
thetic group (P ¼ .068). Primary assisted patency at 2 years for the
GSV, AAV and prosthetic groups was 70%, 52% and 45% respec-
tively. The primary-assisted patency of GSV was signiﬁcantly su-
perior to both AAV (P ¼ .008) and prosthetic grafts (P ¼ .002),
which did not differ signiﬁcantly from one another (P ¼ .479).
Secondary patency at 2 years for the GSV, AAV and prosthetic
groups was 75%, 57% and 46% respectively and again AAV and
prosthetic grafts did not differ signiﬁcantly from one another (P ¼
.212). In Cox regression analysis primary, primary assisted and
secondary patency were positively predicted by GSV (HR 1.65, P ¼
.001; HR 1.65, P ¼ .006; HR 1.72, P ¼ .006 respectively) when
compared to AAV, but there was no difference between AAV and
prosthetic grafts. Neither target artery (popliteal vs. tibial/pedal)
or runoff score, nor statins showed any predictive value. Limb
salvage at 2 years for the GSV, AAV and prosthetic groups was
87%, 77% and 74% respectively with no signiﬁcant differences
among groups.
Conclusion: When GSV is not available, alternative autologous vein
conduits do not offer a signiﬁcant patency advantage in midterm
follow up over prosthetic bypasses for below knee targets.The Receptor for Advanced Glycation End Products (RAGE) and
its Ligands in Plasma and Infrainguinal Bypass Vein
J. Malmstedt
Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Introduction: Objective: To investigate if RAGE and its ligands are
associated with outcome in patients with and without diabetes
undergoing infrainguinal bypass surgery.
Methods: A prospective observational study with at least 3 years
follow upwas conducted in 68 patients (57%male) with (n¼ 38) and
without (n ¼ 30) diabetes undergoing their ﬁrst elective infrain-
guinal vein bypass due to peripheral arterial occlusive disease.
Endosecretory RAGE (esRAGE), S100A12, advanced glycation end
products and carboxymethyl-lysine (CML) were determined in
plasma using ELISA. Inﬂuence of plasma levels on themain outcome
measure (amputation free survival) was evaluated using Cox pro-
portional hazard regression analysis. Plasma levels of esRAGE, CML
and S100A12 in healthy controls (n ¼ 30) without cardiovascular
disease matched for sex and age were compared to patients, using
ManneWhitney U test. S100A12, RAGE, AGE and CML in vein tissue
obtained at bypass surgery were determined using
immunohistochemistry.
Results: Forty-six patients survived with intact leg during a median
follow up of 702 days, (IQR 188 to 899). Seventeen died, and 6
were amputated. High plasma levels of S100A12 were associated
with reduced amputation free survival, (hazard ratio [HR] 2.99;
95% CI 1.24e7.24) when comparing levels above the 75th
percentile with levels below. The increased risk was essentially
unchanged adjusting for age, sex and diabetes (HR 2.58; 95% CI
1.05e6.35).Diabetic patients had higher mean S100A12 plasma levels,
11.75 ng/mL; 95% CI 8.12e15.38 compared to non diabetic pa-
tients 5.01; 3.62e6.41 (P ¼ .002), whereas levels of CML, esRAGE
and AGE were comparable. Mean plasma levels of CML and
S100A12 were higher in patients compared to controls, 1.25 mg/
mL; 95% CI 1.18e1.32 versus 0.89; 0.82e0.96 (P ¼ .001), and 8.73
ng/mL; 95% CI 6.52e10.95 versus 3.47; 2.95e3.99 (P < .001),
respectively. Diabetic patients did not differ from non diabetic
patients in the proportion of vein tissue area stained for AGE
(21%), RAGE (5%), CML (9%) and S100A12 (3%), and staining was
found in all veins with the same percentage in both diabetic and
non diabetic patients.
Conclusion: Plasma levels of S100A12 and CML are elevated in
peripheral arterial occlusive disease and markers of RAGE and its
ligands are found in vein tissue used for bypass. This may indicate a
role for S100A12, CML and RAGE in peripheral arterial disease
complications by activation of the RAGE system.Renal Outcomes Following Fenestrated and Branched
Endografting
T.M. Gonzalez, B. Maurel, J. Sobocinski, A. Hertault, C. Pinçon,
R. Spear, M. Le Roux, R. Azzaoui, S. Haulon
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Introduction: The purpose of this study was to analyze immediate
and long-term renal outcomes (renal function and renal events)
after fenestrated (FEVAR) and branched endovascular aortic
aneurysm repair (BEVAR).
Methods: All FEVAR and BEVAR performed between October 2004
and October 2012 were included in this study. Postoperative acute
renal failure (ARF) was deﬁned and classiﬁed according to the
RIFLE criteria. Renal volume (calculated with a 3D workstation) and
eGFR (estimated with the MDRD formula) were evaluated before
the procedure, before discharge, 12 months after and yearly
thereafter. Renal stent occlusion, dissection, fracture, stenosis,
kink, renal stent related type III endoleak and renal stent sec-
ondary intervention were all considered “renal composite events”
and analyzed. A time-to-event analysis was performed for renal
events and renal secondary interventions.
Results: During the study period, 225 patients were treated with
FEVAR and BEVAR. Renal target vessels (n ¼ 427) were perfused
by fenestrations (n ¼ 274) or branches (n ¼ 53). Median follow-up
was 2.4 years (2.2e2.6). FEVAR and BEVAR were associated with
similar mean renal artery diameter and renal artery angulations.
Preoperative renal stenosis rate was higher with BEVAR (p <
0.021). Technical success was achieved in 96.4% of patients.
Postoperative ARF was depicted in 64 patients (29%), requiring
transient hemodialysis in 12 patients (5.3%) and permanent he-
modialysis in one case (0.44%). An additional 4 patients (1.9%)
required hemodialysis during follow-up. Signiﬁcant decrease in
right renal volume (17.07 cm3; 95% conﬁdence interval (CI),
12.52e21.67), left renal volume (24.55 cm3; 95% CI, 19.14e29.97)
and eGFR (12.54 ml/min per 1.73 m2; 95% CI, 8.43e16.66) were
observed during follow-up (p < 0.000). The 30-day, 1-year and 5-
year freedom from renal composite event was 98.1% (95% CI,
97.2%e99%), 95% (95% CI, 93.5%e96.5%) and 87.5% (95% CI,
84.7%e90%). Freedom for renal composite events was signiﬁ-
cantly higher in FEVAR (p < 0.048) compared to BEVAR. The 30-
day, 1-year and 5-year freedom from renal occlusion was 99.5%
(95% CI, 99%e100%), 98.5% (95% CI, 97.6%e99.4%) and 93.8%
(95% CI, 91.7%e95.9%) after FEVAR and BEVAR (NS). Median time
